Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...
Posted by Michael Wonder on 21 Mar 2022
DoH publishes revised agenda for this month's PBAC meeting
21 March 2022 - This is the first time we can recall that the DoH has published a revised agenda ...
Posted by Michael Wonder on 18 Mar 2022
Public summary documents – November 2021 PBAC meeting (first time rejections and deferrals)
18 March 2022 - The Public Summary Documents (first time rejections and deferrals) from the November 2021 PBAC meeting are now ...
Posted by Michael Wonder on 15 Mar 2022
1 April 2022 price disclosure confirmed prices
15 March 2022 - Confirmed 1 April 2022 prices resulting from the 2022 April cycle of price disclosure have now been ...
Posted by Michael Wonder on 04 Mar 2022
Public summary documents – November 2021 PBAC meeting
4 March 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2021 PBAC ...
Posted by Michael Wonder on 22 Feb 2022
Does the DoH favour some pharmaceutical companies over others?
23 February 2022 - Some interesting insights from version 1 of the agenda for the May 2022 PBAC (intracycle) meeting. ...
Posted by Michael Wonder on 11 Feb 2022
Agenda for the May 2022 PBAC intracycle meeting
11 February 2022 - The agenda for the May 2022 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 07 Feb 2022
DoH publishes revised agenda for next month's PBAC meeting
7 February 2022 - The revised agenda notes three changes. ...
Posted by Michael Wonder on 31 Jan 2022
NICE publishes new combined methods and processes manual and topic selection manual for its health technology evaluation programmes
31 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 28 Jan 2022
Recommendations made by the PBAC – December 2021 intracycle meeting
28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 27 Jan 2022
2022 April price disclosure cycle – indicative prices
27 January 2022 - Indicative 1 April 2022 prices resulting from the 2022 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 24 Jan 2022
Method paper: new version 6.1 comes into force
24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...
Posted by Michael Wonder on 21 Jan 2022
National Medicines Policy Review – publication of submissions
21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...
Posted by Michael Wonder on 14 Jan 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
11 January 2022 - The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. ...